IDiyas

For the Inventor, By the Inventor

North Haven, CT, United States of America

Robert Sibley

USPTO Granted Patents = 23 

 

Average Co-Inventor Count = 9.7

ph-index = 8

Forward Citations = 270(Granted Patents)


Company Filing History:

goldMedal12 out of 1,535 
 
Boehringer Ingelheim International Gmbh
 patents
silverMedal7 out of 70 
 
Bayer Pharmaceuticals Corporation
 patents
bronzeMedal4 out of 780 
 
Bayer Healthcare LLC
 patents

Years Active: 2004-2019

Loading Chart...
Loading Chart...
23 patents (USPTO):
1. 10450314 - Pteridine derivatives as modulators of ROR gamma (2019-10-22),
2. 9598415 - Compounds as modulators of RORγ (2017-03-21),
3. 9573957 - Inhibitors of leukotriene production (2017-02-21),
4. 9403830 - Inhibitors of leukotriene production (2016-08-02),
5. 9242989 - Compounds as modulators of RORγ (2016-01-26),
6. 9079880 - Rho kinase inhibitors (2015-07-14),
7. 9000154 - Rho kinase inhibitors (2015-04-07),
8. 8946203 - Benzodioxane inhibitors of leukotriene production (2015-02-03),
9. 8697911 - Rho kinase inhibitors (2014-04-15),
10. 8450317 - CXCR3 receptor antagonists (2013-05-28),
11. 8362249 - CXCR3 receptor antagonists (2013-01-29),
12. 8093266 - Rho kinase inhibitors (2012-01-10),
13. 7977333 - Substituted pyridines and pyridazines with angiogenesis inhibiting activity (2011-07-12),
14. 7928239 - Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas (2011-04-19),
15. 7897623 - ω-carboxyl aryl substituted diphenyl ureas as p38 kinase inhibitors (2011-03-01),

Title: Innovations by Robert Sibley: A Pioneer in Modulation of ROR Gamma

Introduction

Robert Sibley, an innovative inventor based in North Haven, CT, has made significant contributions to the field of pharmaceutical sciences. With an impressive portfolio of 23 patents, Sibley has focused his research on compounds that act as modulators of ROR gamma, a receptor implicated in various diseases.

Latest Patents

Among Robert Sibley's latest patents are notable inventions contributing to the modulation of ROR gamma. The present inventions encompass compounds of formula (I), wherein the variables are defined to suit the modulation of ROR gamma, aiding in the treatment of related diseases. Additionally, these patents detail processes for synthesizing compounds of formula (I) and include pharmaceutical preparations that utilize these innovative compounds.

Career Highlights

Sibley's career spans prominent institutions where he has leveraged his expertise in pharmaceuticals. He has worked extensively at Boehringer Ingelheim International GmbH and Bayer Pharmaceuticals Corporation. His dedication and pioneering approach have solidified his reputation as a key figure in drug development and therapeutic innovation.

Collaborations

Throughout his career, Robert Sibley have collaborated with esteemed colleagues including Jacques P. Dumas and Uday R. Khire. These partnerships have contributed to the advancement of research in the modulation of ROR gamma, highlighting the importance of teamwork in driving scientific discovery.

Conclusion

Robert Sibley's work in the modulation of ROR gamma exemplifies the impact of innovation in the pharmaceutical industry. His 23 patents reflect a commitment to advancing healthcare solutions, proving that meticulous research and collaboration can lead to groundbreaking developments in medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…